Search

Aim : This study was designed to retrospectively review our experience with the multimodality management of hepatoblastomas (HB). Materials and Methods: Thirteen patients were treated for HB between 2000 and 2007. The clinical presentations, chemotherapy tolerance and response, surgical procedure undertaken, and complications were analysed. Results: Median age of the population was 12 months (3-60 months), with a male-to-female ratio of 3.3:1. Nine patients were treated with neoadjuvant chemotherapy incorporating cisplatin and adriamycin. Primary surgery was done in four patients. Extent of hepatic resection in the operated patients varied. Mixed type was the predominant histopathological diagnosis. Adjuvant chemotherapy was well tolerated with no morbidity or mortality. Five-year event-free survival (EFS) and overall survival (OS) of all the 13 patients is 76.9%. All the nine patients who could complete multimodality treatment are alive with no evidence of disease or complications with median follow-up of 63 months (46-122 months). Conclusions: Treatment of HB with multidisciplinary approach was well tolerated. OS and EFS of patients were comparable with published studies.

Endometrial cancer has shown a rising trend over the past 30 years. The incidence has gone up by 21 % since 2008, and the death rate has increased by more than 100 % over the past two decades [1]. Although there is strong data correlating hyperestrogenism and low-grade endometrial cancers, recently link with higher-grade/stage tumors also has been reported [2]. As the median age of endometrial cancer is 63 years, aging population with an increase in average life span also contributes to rise in incidence. In early-stage disease which comprises almost 85 % of case, advancements in surgical techniques as well as staging, focused/limited radiation, and incorporation of structured chemotherapy have dramatically improved outcomes. In developed countries, stage 3 comprises 12 % and stage 4 less than 5 % of endometrial cancers [4]. Depending on the histology, there is wide variation in response to systemic treatment. Systemic management encompasses chemotherapy, hormone manipulation, and molecularly targeted agents. In high-grade tumors with a rapid growth pattern and visceral metastases, chemotherapy is preferred. With the advent of molecular profiling, cancer signaling pathway mutations in endometrial carcinoma have been understood. Various agents to target these have been developed, and many are still in clinical trials.

9045 Background: The use of immunosuppressants for the treatment of immune related (IR) toxicities from immunoregulatory antibodies, such as ipilimumab is intended to dampen harmful adaptive immune...

Primary lymphoma of the bone is a rare clinical presentation constituting to